DIAGENS-B (02526) surged more than 10% in the afternoon, trading up 10.16% at HK$275.4 as of the time of writing, with a turnover of HK$5.7566 million.

The company recently announced that its self-developed global medical imaging data platform, iMedLoop, has officially gone live. iMedLoop integrates the iMedImage medical imaging base model, the iMedStudio intelligent annotation tool, and the iMedMaaS online model training and publishing platform, creating a complete closed loop around medical data aggregation and governance, intelligent annotation, model training, model publishing, and clinical application.

Notably, DIAGENS-B has also reached cooperation agreements with dozens of institutions, including Hangzhou Data Group Co., Ltd., Legend Holdings Corporation, Wenzhou Municipal Health Commission, Zhengzhou People's Hospital, and the School of Mathematical and Physical Medicine at Zhejiang Normal University. These parties will leverage the platform to collaboratively advance data governance, algorithm innovation, model development, and clinical validation, building a comprehensive ecosystem for medical AI innovation. This initiative aims to explore new pathways for enhancing diagnostic and treatment capabilities, supporting the Healthy China initiative.